Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xanthus Life Sciences has reported encouraging data from a study in which Symadex permitted remyelination by prevention of inflammatory cell infiltration in a multiple sclerosis animal model.
Subscribe to our email newsletter
Symadex was found to produce remyelination (repair of damaged myelin) in the study even after 40 days of inflammatory insult by preventing the infiltration of autoreactive cells into the central nervous system. Treatment proved to be effective in both the acute and chronic forms of the disease.
“The early results from this study showed that the animals in the study, which were paralyzed due to neurological impairment, were able to recover and regain their mobility after treatment with Symadex,” commented Dr Stephen Karlik, professor of diagnostic radiology at the University of Western Ontario.
Symadex (formerly known as C-1311) is a next-generation investigational drug that has shown a potentially novel, targeted mechanism of action in studies of cancer and autoimmune disease.
The drug candidate is currently being evaluated in phase II trials in oncology, and Xanthus expects the new MS study data to support a move towards human testing in the MS indication.